Assets and Liabilities Received as Consideration $ in Thousands |
Oct. 22, 2025
USD ($)
|
|---|---|
| Consolidation of NeuroThera (as described in Note 1a) | |
| Trade payables | $ (131) |
| Net assets received as consideration for deemed issuance of shares by a subsidiary | (579) |
| Cash received as consideration for deemed issuance of shares by a subsidiary | $ (710) |